tetano
Editor, Senior Moderator
Viral Immunol
. 2021 Mar 3.
doi: 10.1089/vim.2020.0321. Online ahead of print.
Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients
Harshad P Patil[SUP] 1 [/SUP], Prajakta S Rane[SUP] 1 [/SUP], Shubham Shrivastava[SUP] 1 [/SUP], Sonali Palkar[SUP] 2 [/SUP], Sanjay Lalwani[SUP] 2 [/SUP], Akhilesh C Mishra[SUP] 1 [/SUP], Vidya A Arankalle[SUP] 1 [/SUP]
Affiliations
Abstract
For the assessment of vaccine-induced immune response and to understand the role of antibodies in neutralization, it is necessary to assess dynamics of various antibodies in patients with different clinical manifestations. This study aims to quantitate circulating levels of IgA/IgG and IgG subtypes induced at different days postonset of symptoms, in severe and nonsevere patients. For this, serum or plasma samples (n = 146) collected from 79 COVID-19 patients were used. Indirect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific IgA, IgG, and IgG subtype specific enzyme-linked immunosorbent assays (ELISAs) were performed. Antibody titers between severe and nonsevere patients were compared at different times postonset of clinical symptoms. Titers in ELISA were compared to neutralizing antibody (Nab) titers determined by plaque reduction neutralization test (PRNT). Over 75% patients were positive for IgA/IgG antibodies in the first week. The ELISA titers did not differ during the first week; however, severe disease exhibited raised titers thereafter. Nab titers correlated with the ELISA titers in mild presentation but not in severe disease. IgA and IgG1 antibodies correlated stronger with Nabs. The findings highlighted that IgA together with IgG play an important in SARS-CoV-2 neutralization. These results will prove useful in assessing efficacy of vaccines and understanding disease pathogenesis.
Keywords: IgA; IgG; IgG1; IgG3; SARS-CoV-2; antibodies.
. 2021 Mar 3.
doi: 10.1089/vim.2020.0321. Online ahead of print.
Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients
Harshad P Patil[SUP] 1 [/SUP], Prajakta S Rane[SUP] 1 [/SUP], Shubham Shrivastava[SUP] 1 [/SUP], Sonali Palkar[SUP] 2 [/SUP], Sanjay Lalwani[SUP] 2 [/SUP], Akhilesh C Mishra[SUP] 1 [/SUP], Vidya A Arankalle[SUP] 1 [/SUP]
Affiliations
- PMID: 33656935
- DOI: 10.1089/vim.2020.0321
Abstract
For the assessment of vaccine-induced immune response and to understand the role of antibodies in neutralization, it is necessary to assess dynamics of various antibodies in patients with different clinical manifestations. This study aims to quantitate circulating levels of IgA/IgG and IgG subtypes induced at different days postonset of symptoms, in severe and nonsevere patients. For this, serum or plasma samples (n = 146) collected from 79 COVID-19 patients were used. Indirect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific IgA, IgG, and IgG subtype specific enzyme-linked immunosorbent assays (ELISAs) were performed. Antibody titers between severe and nonsevere patients were compared at different times postonset of clinical symptoms. Titers in ELISA were compared to neutralizing antibody (Nab) titers determined by plaque reduction neutralization test (PRNT). Over 75% patients were positive for IgA/IgG antibodies in the first week. The ELISA titers did not differ during the first week; however, severe disease exhibited raised titers thereafter. Nab titers correlated with the ELISA titers in mild presentation but not in severe disease. IgA and IgG1 antibodies correlated stronger with Nabs. The findings highlighted that IgA together with IgG play an important in SARS-CoV-2 neutralization. These results will prove useful in assessing efficacy of vaccines and understanding disease pathogenesis.
Keywords: IgA; IgG; IgG1; IgG3; SARS-CoV-2; antibodies.